Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George C. Prendergast

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Cancer Research|March 17, 2011
Perspectives on emerging trends in cancer researchGeorge C Prendergast
Oncoimmunology|November 20, 2012
Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the futureGeorge C Prendergast
Cancer Cell|October 31, 2003
Signal transduction: putting translation before transcriptionGeorge C Prendergast
Breast Disease|February 3, 2005
Farnesyltransferase inhibitors: potential therapeutic for inflammatory breast cancer?George C Prendergast
Cell Cycle (Georgetown, Tex.)|July 6, 2007
Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeastArivudainambi Ramalingam, George C Prendergast
Oncotarget|February 4, 2016
Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancerJames DuHadaway, George C Prendergast
Frontiers in Pharmacology|July 31, 2023
Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's diseaseSunil Thomas, George C Prendergast
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
Targeting farnesyltransferase: is Ras relevant?George C. Prendergast, Wei Du
Cancer Biology & Therapy|May 7, 2005
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's diseaseUma Kamasani, George C Prendergast
Methods in Molecular Biology (Clifton, N.J.)|April 15, 2016
Cancer Vaccines: A Brief OverviewSunil Thomas, George C Prendergast
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Cancer Research|March 17, 2011
Perspectives on emerging trends in cancer researchGeorge C Prendergast
Oncoimmunology|November 20, 2012
Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the futureGeorge C Prendergast
Cancer Cell|October 31, 2003
Signal transduction: putting translation before transcriptionGeorge C Prendergast
Breast Disease|February 3, 2005
Farnesyltransferase inhibitors: potential therapeutic for inflammatory breast cancer?George C Prendergast
Cell Cycle (Georgetown, Tex.)|July 6, 2007
Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeastArivudainambi Ramalingam, George C Prendergast
Oncotarget|February 4, 2016
Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancerJames DuHadaway, George C Prendergast
Frontiers in Pharmacology|July 31, 2023
Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's diseaseSunil Thomas, George C Prendergast
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 16, 2001
Targeting farnesyltransferase: is Ras relevant?George C. Prendergast, Wei Du
Cancer Biology & Therapy|May 7, 2005
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's diseaseUma Kamasani, George C Prendergast
Methods in Molecular Biology (Clifton, N.J.)|April 15, 2016
Cancer Vaccines: A Brief OverviewSunil Thomas, George C Prendergast
Pageof 14